The United States of America, as Represented by the Secretary, Department of Health and Human Services

M.d. Anderson Cancer Center

Michael J Birrer

Anil K Sood

Nancy H Colburn

Chunhua Lu

Zigang Dong

Tomas A Bonome

Powel H Brown

A gene profiling signature for ovarian tumor endothelial cells is disclosed herein. The gene signature can be used to diagnosis or prognosis an ovarian tumor, identify agents to treat an ovarian tumor, to predict the metastatic potential of an ovarian tumor and to determine the effectiveness of ovarian tumor treatments. Thus, methods are provided for identifying agents that can be used to treat ovarian cancer, for determining the effectiveness of an ovarian tumor treatment, or to diagnose or prognose an ovarian tumor. Methods of treatment are also disclosed which include administering a composition that includes a specific binding agent that specifically binds to one of the disclosed ovarian endothelial cell tumor-associated molecules and inhibits ovarian tumor in the subject.

Pro-angiogenic genes in ovarian tumor endothelial cell isolates

The inhibition of AP-1 activity by dominant negative deletion mutants of c-jun is disclosed. This inhibition of AP-1 activity is shown to be associated with inhibition of tumor promoter-induced neoplastic transformation. Therefore, the invention relates to the utilization of dominant negative deletion mutants of c-jun which are inhibitory to tumor promotor-induced neoplastic transformation as therapeutic agents in the prevention and treatment of cancer in mammals.

Dominant negative deletion mutants of C-jun and their use in the prevention and treatment of cancer

Growing community of inventors

Mt. Airy, MD, United States of America

Michael J Birrer